Engineered parasites for delivering protein to the central nervous system (cns)
US-2025057892-A1 · Feb 20, 2025 · US
Pharmaceutical composition for preventing or treating inflammatory diseases including Toxoplasma gondii GRA9 protein or gene encoding the protein as active ingredient
US11939360B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11939360-B2 |
| Application number | US-202217682544-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 28, 2022 |
| Priority date | Mar 16, 2021 |
| Publication date | Mar 26, 2024 |
| Grant date | Mar 26, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition and a health functional food composition for preventing, alleviating or treating inflammatory diseases, including Toxoplasma gondii GRA9 protein or a gene encoding the protein as an active ingredient. The present inventors have identified the C-terminal region essential for the NLRP3-mediated mechanism of action and function of Toxoplasma gondii GRA9 in macrophages, which are host immune cells and confirmed the substantial anti-inflammatory and antibacterial effects and the antiseptic effect in vivo. Accordingly, Toxoplasma gondii GRA9 protein or a gene encoding the protein is expected to be usefully utilized in the field of prevention or treatment of inflammatory diseases caused by an abnormal NLRP3-mediated inflammatory response, including sepsis.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating an inflammatory disease, the method comprising a step of administering to an individual a composition including Toxoplasma gondii GRA9 protein as an active ingredient. 2. The method of claim 1 , wherein the inflammatory disease is sepsis. 3. The method of claim 1 , wherein the GRA9 protein is a C-terminal region corresponding to positions 195 to 288 in an amino acid sequence of the GRA9 protein represented by SEQ ID NO: 1. 4. The method of claim 1 , wherein the GRAS protein inhibits formation of NLRP3 (NLR family pyrin domain containing 3) inflammasome by interacting with NLRP3 in mitochondria of macrophages. 5. The method of claim 1 , wherein the composition reduces NLRP3-mediated inflammation. 6. The method of claim 1 , wherein the composition enhances an anti-inflammatory and antibacterial effect through an increase in polarization and phagocytosis to M2 macrophages.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11939360B2 cover?
- The present invention relates to a pharmaceutical composition and a health functional food composition for preventing, alleviating or treating inflammatory diseases, including Toxoplasma gondii GRA9 protein or a gene encoding the protein as an active ingredient. The present inventors have identified the C-terminal region essential for the NLRP3-mediated mechanism of action and function of To…
- Who is the assignee on this patent?
- Iucf Hyu Erica Campus
- What technology area does this patent fall under?
- Primary CPC classification C07K14/45. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).